Literature DB >> 22807582

Primary cutaneous hydroa vacciniforme-like lymphoma with indolent clinical course: report of two cases and review of literature.

Yang Li1, Xiao-hong Chen, Xiao-ying Tian, Bin Li, Zhi Li.   

Abstract

Primary cutaneous hydroa vacciniforme (HV)-like lymphoma is a rare, Epstein-Barr virus-associated cutaneous neoplasm characterized by photosensitive papulovesicular eruption and usually associated with poor prognosis. This report presents 2 cases of primary cutaneous HV-like lymphoma with unusual indolent clinical course and favorable prognosis during the follow-up periods of 2 and 3 years, respectively. Both patients presented with erythema, papulovesicles, scars, ulcerations, and edema on the face and extremities. Skin biopsies revealed epidermal vesicle with small- to medium-sized atypical lymphoid cells infiltrating in the dermis and subcutis. The lymphoid cells were strongly immunoreactive to CD8 and CD56. The Epstein-Barr virus genomes were also found in both skin biopsies. By genetic analysis, one of patients showed T-cell receptor-γ gene clonal rearrangement. The patients underwent glucocorticoid treatment and obtained remarkable clinical improvement with regression of skin lesions. No sign of recurrence and extracutaneous manifestation was found during the period of follow-up. A long-term follow-up is suggested to be performed to inspect the progression for this tumor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22807582     DOI: 10.1177/1066896912453200

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  2 in total

1.  Adult-onset Hydroa Vacciniforme: A Rare Occurrence or a Lymphoma Premonition?

Authors:  Ankita Sangwan; Kamal Aggarwal; Sarabjit Kaur; Vijay K Jain
Journal:  Indian Dermatol Online J       Date:  2017 Nov-Dec

Review 2.  Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Diseases in Chinese Mainland.

Authors:  Junhong Ai; Zhengde Xie
Journal:  Front Pediatr       Date:  2018-10-09       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.